```
=> b reg
FILE 'REGISTRY' ENTERED AT 16:03:39 ON 31 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JUL 2008  HIGHEST RN 1037244-07-7
DICTIONARY FILE UPDATES:  30 JUL 2008  HIGHEST RN 1037244-07-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l10
L6      2305437 SEA FILE=REGISTRY ABB=ON  PLU=ON  46.150.18/RID AND NC5/ES
L8              STR
```




```
VAR G1=O/S
REP G2=(1-5) C
REP G3=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E6 C  AT   3
ECOUNT  IS E5 C  E1 N  AT   6

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L10         219 SEA FILE=REGISTRY SUB=L6 SSS FUL L8

100.0% PROCESSED   59258 ITERATIONS                          219 ANSWERS
SEARCH TIME: 00.00.01



=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:03:48 ON 31 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
```

FILE COVERS 1907 - 31 Jul 2008 VOL 149 ISS 5
FILE LAST UPDATED: 30 Jul 2008 (20080730/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l13 tot

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:370915 HCAPLUS
DN 140:391296
TI Preparation of aryloxyalkylamine derivatives as H3 receptor ligands
IN Best, Desmond John; Bruton, Gordon; Heightman, Thomas Daniel; Orlek, Barry Sidney
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004037800	A1	20040506	2003WO-EP0011649	20031020
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2003274053	A1	20040513	2003AU-000274053	20031020
	EP-----1554260	A1	20050720	2003EP-000758032	20031020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP--2006512404	T	20060413	2005JP-000501523	20031020
	US-20060052597	A1	20060309	2005US-000532371	20050421
PRAI	2002GB-000024558	A	20021022		
	2002GB-000024677	A	20021023		
	2002GB-000024678	A	20021023		
	2002GB-000024679	A	20021023		
	2002GB-000024783	A	20021024		
	2003GB-000003467	A	20030214		
	2003WO-EP0011649	W	20031020		

OS MARPAT 140:391296
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title novel benzyloxy compds. [I; R1 = II (wherein R4a = alkyl, oxo, (hetero)aryl, heterocyclyl; R5a = halo, OH, CN, etc.; m = 1-2; p = 0-3; when p = 2, said R4a groups may instead form a bridging group consisting of 1-2 methylene groups), substituted SO2NH2, III (R4b = alkyl, OH, aryl, heterocyclyl; r = 0-2), etc.; R2 = halo, alkyl, alkoxy, CN, NH2, CF3; n = 0-2; R3 = (CH2)qNR11R12, IV (q = 2-4; R11, R12 = alkyl; NR11R12 = heterocyclyl; R13 = alkyl, cycloalkyl, alkylcycloalkyl; R14 = halo, alkyl, haloalkyl, OH, dialkylamino, alkoxy; f, k = 0-2; g = 0-2; h = 0-3 (g and h cannot both be 0))], useful in the treatment of neurol. and psychiatric disorders, were prepared Thus, reacting 4-[3-(piperidin-1-yl)propoxy]benzoic acid hydrochloride with 4-phenylpiperazine afforded V which exhibited pKb of >8.5 in the histamine H3 functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.

IT 685871-07-2P 685871-09-4P 685871-56-1P
685872-21-3P 685872-23-5P 685872-96-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryloxyalkylamine derivs. as H3 receptor ligands)

IT 685871-06-1P 685871-08-3P 685871-10-7P
685871-11-8P 685871-12-9P 685871-13-0P
685871-14-1P 685871-15-2P 685871-16-3P
685871-17-4P 685871-18-5P 685871-19-6P
685871-20-9P 685871-21-0P 685871-22-1P
685871-23-2P 685871-25-4P 685871-26-5P

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

685871-27-6P 685871-28-7P 685871-29-8P
685871-30-1P 685871-31-2P 685871-32-3P
685871-33-4P 685871-34-5P 685871-35-6P
685871-36-7P 685871-37-8P 685871-38-9P
685871-39-0P 685871-40-3P 685871-41-4P
685871-42-5P 685871-43-6P 685871-44-7P
685871-45-8P 685871-46-9P 685871-47-0P
685871-48-1P 685871-49-2P 685871-50-5P
685871-51-6P 685871-52-7P 685871-53-8P
685871-54-9P 685871-55-0P 685871-57-2P
685871-58-3P 685871-59-4P 685871-60-7P
685871-61-8P 685871-62-9P 685871-63-0P
685871-64-1P 685871-65-2P 685871-66-3P
685871-67-4P 685871-68-5P 685871-69-6P
685871-70-9P 685871-71-0P 685871-72-1P
685871-73-2P 685871-74-3P 685871-75-4P
685871-76-5P 685871-77-6P 685871-78-7P
685871-79-8P 685871-80-1P 685871-81-2P
685871-82-3P 685871-83-4P 685871-84-5P
685871-85-6P 685871-86-7P 685871-87-8P
685871-88-9P 685871-89-0P 685871-90-3P
685871-92-5P 685871-93-6P 685871-95-8P
685871-97-0P 685871-99-2P 685872-01-9P
685872-03-1P 685872-05-3P 685872-07-5P
685872-08-6P 685872-09-7P 685872-10-0P
685872-12-2P 685872-14-4P 685872-16-6P
685872-17-7P 685872-19-9P 685872-26-8P
685872-28-0P 685872-30-4P 685872-32-6P
685872-34-8P 685872-35-9P 685872-36-0P
685872-37-1P 685872-38-2P 685872-39-3P
685872-40-6P 685872-41-7P 685872-42-8P
685872-43-9P 685872-44-0P 685872-45-1P
685872-46-2P 685872-47-3P 685872-48-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryloxyalkylamine derivs. as H3 receptor ligands)

IT 685872-97-3P, 1-[4-(3-(Piperidin-1-yl)propoxy)benzoyl]homopiperazine dihydrochloride 685873-05-6P, 1-(tert-Butoxycarbonyl)-4-[4-(3-(piperidin-1-yl)propoxy)-2-trifluoromethylbenzoyl]piperazine 685873-06-7P, 1-[4-(3-(Piperidin-1-yl)propoxy)-2-trifluoromethylbenzoyl]piperazine dihydrochloride 685873-08-9P 685873-09-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryloxyalkylamine derivs. as H3 receptor ligands)

IT 685871-07-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryloxyalkylamine derivs. as H3 receptor ligands)

RN 685871-07-2 HCAPLUS
CN Methanone, 1-piperazinyl[4-[3-(1-piperidinyl)propoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

=> d bib abs hitstr l15 tot

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:847770 HCAPLUS
DN 137:353063
TI Preparation of piperazines as antidiabetic agents
IN Maruta, Katsunori; Iwai, Kiyotaka; Yoshida, Kozo; Nagata, Tatsu
PA Sumitomo Pharmaceuticals Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP--2002322163	A	20021108	2001JP-000123655	20010420 <--
PRAI 2001JP-000123655		20010420	<--	

OS MARPAT 137:353063
GI



I

AB The compds. I (Ar1 = substituted Ph, (un)substituted monocyclic heteroaryl, dicyclic aryl, dicyclic heteroaryl; Ar2 = (un)substituted phenylene, dicyclic arylene, monocyclic heteroarylene, dicyclic heteroarylene; A = methylene, ethylene; R = XYAr3; X = C1-3 alkylene; Y = single bond, NR1, O; R1 = H, Me, Et; Ar3 = (un)substituted Ph, monocyclic heteroaryl, dicyclic aryl, dicyclic heteroaryl) or their pharmaceutically acceptable salts are prepared 2-(5-Ethyl-2-pyridyl)ethanol was esterified with mesyl chloride in the presence of Et3N in THF at room temperature for 1 h and reacted with 4-[[4-[4-(trifluoromethyl)benzyl]-1-piperazinyl]carbonyl]phenol in the presence of K2CO3 in DMF at 100° for 5 h to give 63% 1-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzoyl]-4-[4-(trifluoromethyl)benzyl]piperazine, which was administered in mice at 128 mg/kg/day, resulting in blood glucose level 522.3±89.4 mg/dL, while 548.8±61.6 mg/dL at 0 mg/kg/day.
IT 474658-87-2P 474658-93-0P 474659-01-3P
474659-12-6P 474659-14-8P 474659-16-0P
474659-17-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazines as antidiabetic agents)
RN 474658-87-2 HCAPLUS
CN Methanone, [4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl][4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 474658-93-0 HCAPLUS
CN Methanone, [4-(2-pyridinylmethoxy)phenyl][4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 474659-01-3 HCAPLUS
CN Methanone, [4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl][4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 474659-12-6 HCAPLUS
CN Methanone, [4-[3-(2-pyridinyl)propoxy]phenyl][4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 474659-14-8 HCAPLUS
CN Methanone, [4-[2-(2-pyridinyl)ethoxy]phenyl][4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 474659-16-0 HCAPLUS
CN Methanone, [4-[3-(3-pyridinyl)propoxy]phenyl][4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 474659-17-1 HCAPLUS
CN Methanone, [4-[3-(4-pyridinyl)propoxy]phenyl][4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]- (CA INDEX NAME)



L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:754339 HCAPLUS
DN 137:279100
TI Preparation of non-imidazole aryl alkylamines as histamine H3 receptor antagonists
IN Beavers, Lisa Selsam; Gadski, Robert Alan; Hipskind, Philip Arthur; Lindsley, Craig William; Lobb, Karen Lynn; Nixon, James Arthur; Pickard, Richard Todd; Schaus, John Mehnert; Takakuwa, Takako; Watson, Brian Morgan
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002076925	A2	20021003	2002WO-US0006644	20020321 <--
WO--2002076925	A3	20030918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2441080	A1	20021003	2002CA-002441080	20020321 <--
AU----2002254114	A1	20021008	2002AU-002254114	20020321 <--
EP-----1379493	A2	20040114	2002EP-000723329	20020321 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP--2004532834	T	20041028	2002JP-000576188	20020321 <--
US-20040110748	A1	20040610	2003US-000472675	20030918 <--
US-----7314937	B2	20080101		
PRAI 2001US-00278230P	P	20010323	<--	
2002WO-US0006644	W	20020321	<--	

OS MARPAT 137:279100
GI



I



II

AB The title compds. [I; X = O, NR7, S; R1 = H, alkyl, haloalkyl, etc.; R2 = R1, COR1; or NR1R2 = (un)substituted 4-6 membered carbon ring wherein one of said carbons is optionally replaced by one of O, S, NR1 or CO; R3 = cycloalkylene, (un)substituted alkylene; R4 = H, halo, alkyl, etc.; R5 = H, alkyl; R6 = H, halo, etc.; R7 = H, alkyl, haloalkyl, etc.; R8 = H, a bond, alkyl, etc.] and their pharmaceutically acceptable salts which have selective histamine-H3 receptor antagonist activity (biol. data given), and are useful in treating obesity and other histamine H3 receptor-related diseases, were prepared Thus, reacting p-hydroxyacetophenone with 3-chloro-N,N-diethyl-N-propylamine in the presence of NaH in THF and DMF

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(92% yield) followed by reductive amination of the resulting intermediate with 2-(dimethylamino)ethylamine in the presence of NaCNBH3 in EtOH afforded 93% II.
IT 464898-55-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of non-imidazole aryl alkylamines as histamine H3 receptor antagonists)
RN 464898-55-3 HCAPLUS
CN Methanone, (hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:462022 HCAPLUS
DN 77:62022
OREF 77:10267a,10270a
TI 1-(2-Hydroxy-5-chlorobenzoyl)piperazine derivatives
IN Brisson, Henri; Vrancea, Serge
PA Laboratoires Biosedra
SO Ger. Offen., 9 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE-----2155857	A	19720518	1971DE-002155857	19711110 <--
BE------774447	A1	19720214	1971BE-000109738	19711025 <--
PRAI 1970GB-000053695	A	19701111 <--		

GI For diagram(s), see printed CA Issue.
AB Twelve title compds. [I; R = H or 3-pyridylcarbonyl; R1 = Me, CH2CH(OH)Me, CH2CO2Et, m-ClC6H4, 2,5-Me2C6H3, 5,2-Cl(HO)C6H3CO, CH2CONH2, or 2-(3-pyridylcarbonyloxy)propyl], useful as antiinflammatory and analgesic agents, were prepared Thus, refluxing 242 g Et 2-(1-piperazinyl)acetate and 264 g 5,2-Cl(HO)C6H3COCl in pyridine gave 320 g I (R = H, R1 = CH2CO2Et) (II). Heating 117 g II and 114.8 g nicotinic anhydride 2 hr on an oil bath (145-60°) gave 115 g I (R = 3-pyridylcarbonyl, R1 = CH2CO2Et). Refluxing 29 g I (R = R1 = H) and 70 g propylene oxide 30 min in MeOH gave 23 g I (R = H, R1 = CH2CHMeOH).
IT 37133-68-9P 37133-69-0P 37133-82-7P
37133-83-8P 37133-84-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37133-68-9 HCAPLUS
CN 1-Piperazineacetic acid, 4-[5-chloro-2-[(3-pyridinylcarbonyl)oxy]benzoyl]-, ethyl ester (CA INDEX NAME)





RN 37133-69-0 HCAPLUS
CN 3-Pyridinecarboxylic acid, 4-chloro-2-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]phenyl ester (CA INDEX NAME)



RN 37133-82-7 HCAPLUS
CN 3-Pyridinecarboxylic acid, 2-[4-[5-chloro-2-[(3-pyridinylcarbonyl)oxy]benzoyl]-1-piperazinyl]-1-methylethyl ester, hydrochloride (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)





● x HCl

RN 37133-83-8 HCAPLUS
CN 3-Pyridinecarboxylic acid, 4-chloro-2-[4-(4-methyl-1-piperazinyl)carbonyl]phenyl ester (9CI) (CA INDEX NAME)





RN 37133-84-9 HCAPLUS
CN 3-Pyridinecarboxylic acid, 4-chloro-2-[[4-(2,5-dimethylphenyl)-1-piperazinyl]carbonyl]phenyl ester (CA INDEX NAME)



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 16:04:43 ON 31 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:04:43 ON 31 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:04:43 ON 31 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l18 tot
```

L18 ANSWER 1 OF 1 USPATFULL on STN
AN 2006:61427 USPATFULL
TI Aryloxyalkylamine derivatives as h3 receptor ligands
IN Best, Desmond John, Essex, UNITED KINGDOM
Bruton, Gordon, Essex, UNITED KINGDOM
Heightman, Thomas Daniel, Essex, UNITED KINGDOM
Orlek, Barry Sidney, Essex, UNITED KINGDOM
PI US-20060052597 A1 20060309
AI 2003US-000532371 A1 20031020 (10)
2003WO-EP0011649 20031020
20050421 PCT 371 date
PRAI 2002GB-000024558 20021022
2002GB-000024677 20021023
2002GB-000024678 20021023
2002GB-000024679 20021023
2002GB-000024783 20021024
2003GB-000003467 20030214
DT Utility
FS APPLICATION
LREP GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 685871-07-2P 685871-09-4P 685871-56-1P
685872-21-3P 685872-23-5P 685872-96-2P
(preparation of aryloxyalkylamine derivs. as H3 receptor ligands)
IT 685871-06-1P 685871-08-3P 685871-10-7P
685871-11-8P 685871-12-9P 685871-13-0P
685871-14-1P 685871-15-2P 685871-16-3P
685871-17-4P 685871-18-5P 685871-19-6P
685871-20-9P 685871-21-0P 685871-22-1P
685871-23-2P 685871-25-4P 685871-26-5P
685871-27-6P 685871-28-7P 685871-29-8P
685871-30-1P 685871-31-2P 685871-32-3P
685871-33-4P 685871-34-5P 685871-35-6P
685871-36-7P 685871-37-8P 685871-38-9P
685871-39-0P 685871-40-3P 685871-41-4P
685871-42-5P 685871-43-6P 685871-44-7P
685871-45-8P 685871-46-9P 685871-47-0P
685871-48-1P 685871-49-2P 685871-50-5P
685871-51-6P 685871-52-7P 685871-53-8P
685871-54-9P 685871-55-0P 685871-57-2P
685871-58-3P 685871-59-4P 685871-60-7P
685871-61-8P 685871-62-9P 685871-63-0P
685871-64-1P 685871-65-2P 685871-66-3P
685871-67-4P 685871-68-5P 685871-69-6P
685871-70-9P 685871-71-0P 685871-72-1P
685871-73-2P 685871-74-3P 685871-75-4P
685871-76-5P 685871-77-6P 685871-78-7P
685871-79-8P 685871-80-1P 685871-81-2P
685871-82-3P 685871-83-4P 685871-84-5P
685871-85-6P 685871-86-7P 685871-87-8P
685871-88-9P 685871-89-0P 685871-90-3P
685871-92-5P 685871-93-6P 685871-95-8P
685871-97-0P 685871-99-2P 685872-01-9P
685872-03-1P 685872-05-3P 685872-07-5P
685872-08-6P 685872-09-7P 685872-10-0P
685872-12-2P 685872-14-4P 685872-16-6P
685872-17-7P 685872-19-9P 685872-26-8P
685872-28-0P 685872-30-4P 685872-32-6P
685872-34-8P 685872-35-9P 685872-36-0P
685872-37-1P 685872-38-2P 685872-39-3P

L18 ANSWER 1 OF 1 USPATFULL on STN (Continued)
685872-40-6P 685872-41-7P 685872-42-8P
685872-43-9P 685872-44-0P 685872-45-1P
685872-46-2P 685872-47-3P 685872-48-4P
(prepn. of aryloxyalkylamine derivs. as H3 receptor ligands)
IT 685872-97-3P, 1-[4-(3-(Piperidin-1-yl)propoxy)benzoyl]homopiperazine dihydrochloride 685873-05-6P, 1-(tert-Butoxycarbonyl)-4-[4-(3-(piperidin-1-yl)propoxy)-2-trifluoromethylbenzoyl]piperazine 685873-06-7P, 1-[4-(3-(Piperidin-1-yl)propoxy)-2-trifluoromethylbenzoyl]piperazine dihydrochloride 685873-08-9P 685873-09-0P
(preparation of aryloxyalkylamine derivs. as H3 receptor ligands)
IT 685871-07-2P
(preparation of aryloxyalkylamine derivs. as H3 receptor ligands)
RN 685871-07-2 USPATFULL
CN Methanone, 1-piperazinyl[4-[3-(1-piperidinyl)propoxy]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

```
=> d bib abs hitstr l20 tot
```

L20 ANSWER 1 OF 2 USPATFULL on STN
AN 2004:145076 USPATFULL
TI Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
IN Beavers, Lisa Selsam, Franklin, IN, UNITED STATES
Gadski, Robert Alan, Indianapolis, IN, UNITED STATES
Hipskind, Philip Arthur, New Palestine, IN, UNITED STATES
Lindsley, Craig William, Schwenksville, PA, UNITED STATES
Lobb, Karen Lynn, Indianapolis, IN, UNITED STATES
Nixon, James Arthur, Indianapolis, IN, UNITED STATES
Pickard, Richard Todd, Noblesville, IN, UNITED STATES
Schaus, John Mehnert, Zionsville, IN, UNITED STATES
Takakuwa, Takako, Indianapolis, IN, UNITED STATES
Watson, Brian Morgan, Carmel, IN, UNITED STATES
PI US-20040110748 A1 20040610
US-----7314937 B2 20080101
AI 2003US-000472675 A1 20030918 (10)
2002WO-US0006644 20020321 <--
DT Utility
FS APPLICATION
LREP ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2822
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 464898-55-3P
(preparation of non-imidazole aryl alkylamines as histamine H3 receptor antagonists)
RN 464898-55-3 USPATFULL
CN Methanone, (hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



L20 ANSWER 2 OF 2 USPAT2 on STN
AN 2004:145076 USPAT2
TI Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
IN Beavers, Lisa Selsam, Franklin, IN, UNITED STATES
Gadski, Robert Alan, Indianapolis, IN, UNITED STATES
Hipskind, Philip Arthur, New Palestine, IN, UNITED STATES
Lindsley, Craig William, Schwenksville, PA, UNITED STATES
Lobb, Karen Lynn, Indianapolis, IN, UNITED STATES
Nixon, James Arthur, Indianapolis, IN, UNITED STATES
Pickard, Richard Todd, Noblesville, IN, UNITED STATES
Schaus, John Mehnert, Zionsville, IN, UNITED STATES
Takakuwa, Takako, Indianapolis, IN, UNITED STATES
Watson, Brian Morgan, Carmel, IN, UNITED STATES
PA Eli Lilly and Company, Indianapolis, IN, UNITED STATES (U.S. corporation)
PI US-----7314937 B2 20080101
WO--2002076925 20021003 <--
AI 2002US-000472675 20020321 (10) <--
2002WO-US0006644 20020321 <--
20030918 PCT 371 date
DT Utility
FS GRANTED
EXNAM Primary Examiner: Seaman, D. Margaret
LREP Wood, Dan L.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 464898-55-3P
(preparation of non-imidazole aryl alkylamines as histamine H3 receptor antagonists)
RN 464898-55-3 USPAT2
CN Methanone, (hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 15:43:57 ON 31 JUL 2008)

     FILE 'HCAPLUS' ENTERED AT 15:44:09 ON 31 JUL 2008
L1            1 US20060052597 /PN

     FILE 'REGISTRY' ENTERED AT 15:44:23 ON 31 JUL 2008

     FILE 'HCAPLUS' ENTERED AT 15:44:25 ON 31 JUL 2008
L2              TRA L1 1- RN :      229 TERMS

     FILE 'REGISTRY' ENTERED AT 15:44:25 ON 31 JUL 2008
L3          229 SEA L2
L4          198 L3 AND 46.150.18/RID AND NC5/ES
L5              STR
L6      2305437 46.150.18/RID AND NC5/ES
L7            0 L5  SUB=L6 SAM
L8              STR L5
L9           13 L8 SAM SUB=L6
L10         219 L8 FULL SUB=L6
                SAV TEM J371C1A/A L10
L11         128 L10 AND L3
L12          91 L10 NOT L11

     FILE 'HCAPLUS' ENTERED AT 15:52:28 ON 31 JUL 2008
L13           1 L11
L14          12 L12
L15           3 L14 AND (PD<=20021020 OR PRD<=20021020 OR AD<=20021020)

     FILE 'HCAOLD' ENTERED AT 15:54:40 ON 31 JUL 2008
L16           0 L11
L17           0 L12

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 15:54:47 ON 31 JUL 2008
L18           1 L11
L19           7 L12
L20           2 L19 AND (PD<=20021020 OR PRD<=20021020 OR AD<=20021020)

     FILE 'REGISTRY' ENTERED AT 16:01:33 ON 31 JUL 2008
L21           6 E14-19
```